Post by Ron Hollander, Executive Director
The recently concluded 2015 Symposium of the North American Neuroendocrine Tumor Society (NANETS) was the largest gathering of NET specialists hosted by the Society. In opening the conference’s Clinical Science Symposium, Dr. George Fisher, Stanford Professor and NETRF Scientific Advisory Chair, reflected on the enormous progress over the last few years: from relatively few trials in NETs to the day’s presentations on three successful trials including:
- The NETTER-1 trial demonstrating the improvement in progression-free survival (PFS) of a PRRT treatment using 177-Lu-Dotatate for patients with midgut NETs
- The RADIANT-4 trial on the safety and effectiveness of therapies in delaying PFS for NETs of Lung/Gastrointestinal origin.
- The TELESTAR trial demonstrating the effectiveness of therapy in improved symptom control for patients with Carcinoid Syndrome
The two-day gathering also included a wide range of panels on current research for possible new treatments (including immunotherapy) for NETs and several case studies that illuminated the often difficult treatment decisions and multi-disciplinary processes that characterize NET management.
Picture: CFCF Researchers Dr. Diane Reidy Lagunes, Memorial Sloan Kettering Cancer Center, and Dr. Pamela Kunz, Stanford University Cancer Institute, discuss immunotherapy for NETs on a NANETS panel.